<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043559</url>
  </required_header>
  <id_info>
    <org_study_id>Local/2019/DR-01</org_study_id>
    <secondary_id>IRB 24/07/2019</secondary_id>
    <nct_id>NCT04043559</nct_id>
  </id_info>
  <brief_title>Cortical Cerebellar Infarctions Associated With Patent Foramen Ovale in Young Stroke Patients</brief_title>
  <official_title>Small Cortical Cerebellar Infarctions Are Associated With Patent Foramen Ovale in Young Cryptogenic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator retrospectively analyzed consecutive young (&lt;60 years) cryptogenic stroke
      patients with Patient Foramen Ovale (PFO) recruited between January 2016 and May 2019 in our
      center, and compared these patients with sex- and age-matched controls with cryptogenic
      stroke without PFO. Analyzed baseline characteristics: sex, age, cardiovascular risk factors,
      history of stroke, and cortical/subcortical localization, arterial territory, number of
      lesions, and lesion size of the acute symptomatic infarction, together with the ROPE score.
      The presence and the number of acute and chronic SCCI lesions were assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of infarction lesions</measure>
    <time_frame>day 1</time_frame>
    <description>Number (increase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>infarction location</measure>
    <time_frame>day 1</time_frame>
    <description>anterior, posterior, or mixed anterior-posterior circulation and the cortical/subcortical/corticosubcortical location of infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>size of subcortical lesion</measure>
    <time_frame>day 1</time_frame>
    <description>&lt; or &gt;15mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of multiterritorial infarction</measure>
    <time_frame>day 1</time_frame>
    <description>mixed anterior-posterior circulation or bilateral anterior circulation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Infarction</condition>
  <arm_group>
    <arm_group_label>patients with an acute symptomatic infarction</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>controls with cryptogenic stroke</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI scanner</intervention_name>
    <description>MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.</description>
    <arm_group_label>controls with cryptogenic stroke</arm_group_label>
    <arm_group_label>patients with an acute symptomatic infarction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast transoesophageal echocardiography</intervention_name>
    <description>Contrast transoesophageal echocardiography (including Valsalva manoeuvre)</description>
    <arm_group_label>controls with cryptogenic stroke</arm_group_label>
    <arm_group_label>patients with an acute symptomatic infarction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive young (&lt;60 years) cryptogenic stroke patients with PFO recruited between
        January 2016 and May 2019 in our center, and compared these patients with sex- and
        age-matched controls with cryptogenic stroke without PFO.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients : young (&lt;60 years) adult patients,

          -  Patient recruited and registered in our stroke database between January 2016 and May
             2016 of our center (Nîmes University Hospital, France),

          -  Patients presenting with an acute symptomatic infarction (confirmed by
             diffusion-weighted MRI) of unknown origin

          -  Controls : age-matched controls with cryptogenic stroke without PFO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitri RENARD</last_name>
    <phone>04 66 68 32 61</phone>
    <email>dimitri.renard@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri RENARD</last_name>
      <phone>04 66 68 32 61</phone>
      <email>dimitri.renard@chu-nimes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Infarction</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

